Embecta

Embecta Accounts Payable

The Accounts Payable of Embecta (EMBC) as of Nov 21, 2026 is 74.20 M USD. In the previous year, Accounts Payable was 91.00 M USD — a change of -18.46% (lower).

Accounts Payable

74.20 MUSD

YoY

-18.46%

Last updated:

Accounts Payable of Embecta is 2025 74.20 M USD. Accounts Payable of Embecta was 2024 91.00 M USD. It decreases by -18.46% lower compared to the previous year.

The Embecta Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
47.00 M USD
Jan 1, 2020
50.00 M USD
Jan 1, 2021
54.20 M USD
Jan 1, 2022
41.40 M USD
Jan 1, 2023
53.50 M USD
Jan 1, 2024
91.00 M USD
Jan 1, 2025
74.20 M USD
The Embecta Accounts Payable history
YEARAccounts PayableYoY
74.20 MUSD-18.46%
91.00 MUSD+70.09%
53.50 MUSD+29.23%
41.40 MUSD-23.62%
54.20 MUSD+8.40%
50.00 MUSD+6.38%
47.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Accounts Payable of Embecta is 74.20 M USD in 2025.

Accounts Payable of Embecta changed from 91.00 M USD to 74.20 M USD, representing a -18.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Embecta since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Embecta

All Key Metrics — Embecta